Cost-Effectiveness of First-Line Versus Second-Line Pembrolizumab or Chemotherapy in Patients With Microsatellite-Instability-High/Mismatch Repair-Deficient Advanced Colorectal Cancer

• Үндсэн зохиолчид: Tan Chongqing (Зохиогч), Li Sini (Зохиогч), Zeng Xiaohui (Зохиогч), Peng Liubao (Зохиогч), Peng Ye (Зохиогч), Qin Shuxia (Зохиогч), Wang Liting (Зохиогч), Wu Meiyu (Зохиогч), Wan Xiaomin (Зохиогч)
• Формат: Ном
• Хэвлэсэн: Frontiers Media S.A., 2021-12-01T00:00:00Z.
• Нөхцлүүд: article
• Онлайн хандалт: Connect to this object online.

Background: Pembrolizumab is a guideline-recommended, both first- and second-line treatment option for microsatellite-instability-high (MSI-H)/mismatch repair-deficient (dMMR)advanced colorectal cancer patients. The aim of the present study is to investigates the health and economic outcomes of thre...